In Practice

A qualitative analysis of seven ivermectin formulations in South Africa

Q E Bhorat, A E Bhorat


Some South African (SA) healthcare practitioners are promoting the prescription and use of products claiming to contain ivermectin for the treatment and/or prevention of COVID-19 in SA. This study qualitatively analysed seven samples of ivermectin formulations (5 tablet and 2 capsule formulations) being sold in SA for human use. The samples were analysed using a high-performance liquid chromatography instrument connected to a Sciex X500R quadrupole time-of-flight high-resolution mass spectrometer. The study found that all the samples had both the major homologues of ivermectin (B1a and B1b) and also that 4 out of the 5 tablet formulations tested had at least one additional undeclared active pharmaceutical ingredient.

Authors' affiliations

Q E Bhorat, Soweto Clinical Trials Centre, Johannesburg, South Africa

A E Bhorat, Soweto Clinical Trials Centre, Johannesburg, South Africa

Full Text

PDF (104KB)


Ivermectin; COVID-19; Qualitative analysis; Active pharmaceutical ingredients; Unregistered medication

Cite this article

South African Medical Journal 2021;111(4):288-290. DOI:10.7196/SAMJ.2021.v111i4.15630

Article History

Date submitted: 2021-02-18
Date published: 2021-02-18

Article Views

Abstract views: 11882
Full text views: 9447

Comments on this article

*Read our policy for posting comments here